DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Dooley KE, Sayre P, Borland J. et al.
Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.
J Acquir Immune Defic Syndr 2013;
62: 21-27
We do not assume any responsibility for the contents of the web pages of other providers.